Resources
3 Results (showing 1 - 3)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 9/25/2023 (updated 3/27/2024)
The U.S. Department of Health and Human Services (HHS) has now added American Sign Language (ASL) services to the 988 Suicide and Crisis Lifeline. An ongoing effort of the HHS is to expand accessibility to behavioral health care for underserved communities, which includes individuals who are Deaf and Hard of Hearing.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.